Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients

Figure 1 Flowchart of screening and recruitment of study subjects.

Figure 2 Adverse event rate distribution between the first-line and rescue treatment groups. The percentage on the y-axis was calculated by dividing the number of reported adverse events (AEs) in one group by the total patient number of that group. The dark-blue bars (first-line treatment group) and the brown bars (rescue treatment group) show the patients who discontinued the vonoprazan-amoxicillin dual therapy due to AE. AE: Adverse event.